Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application

− 177Lutetium-labelled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is a highly optimized, next generation therapeutic radiopharmaceutical −− Newly launched Blue Earth Therapeutics rapidly advancing lead candidate into Phase 1/2 clinical development –OXFORD, United Kingdom & BURLINGTON, Mass.--...

Related Keywords

Germany ,Italy ,Milan ,Lombardia ,United States ,United Kingdom ,Munich ,Bayern ,Scintomics Gmb ,Georgina Mowatt ,Davide Gauden ,Mike Beyer ,Priscilla Harlan ,Company Investigational New Drug Application ,Drug Administration ,Sam Brown Inc ,Bracco Group ,Technical University Of Munich ,Nuclear Medicine ,Corporate Communications ,Prostate Specific Membrane Antigen ,Blue Earth Therapeutics ,Investigational New Drug Application ,Blue Earth Therapeutic ,Earth Therapeutics ,Chief Executive Officer ,Radiohybrid Prostate Specific Membrane Antigen ,Prostate Specific Membrane Antigen Targeted ,Technical University ,Blue Earth Diagnostics ,Scintomics Gmbh ,Blue Earth ,Bracco Imaging ,Interventional Radiology ,Cardiac Catheterization ,Magnetic Resonance Imaging ,Contrast Enhanced Ultrasound ,